Only in Titles

Search results for: ADL

paperclip

#36180101   // To Up

Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.

This exploratory analysis investigated the potential use of the multibiomarker disease activity (MBDA) score to support biosimilarity assessments using data from two randomised controlled trials (RCTs) of biosimilar infliximab (IFX-qbtx) and biosimilar adalimumab (ADL-afzb) versus EU-sourced infliximab (Remicade; IFX-EU) and adalimumab (Humira; ADL-EU) reference products, respectively, both conducted in adult patients with active rheumatoid arthritis.
Jonathan Kay, Amy E Bock, Muhammad Rehman, Wuyan Zhang, Min Zhang, Noriko Iikuni, Daniel F Alvarez

2244 related Products with: Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.